Post-liver transplant hepatitis C virus recurrence: An unresolved thorny problem

World Journal of Gastroenterology

Volumn 20, Issue 32, 2014, Pages 11095-11115

  Grassi, Alberto ^a   Ballardini, Giorgio ^a  

^a Infermi Hospital   (Italy)

Author keywords

Graft rejection; Hepatitis C antigens; Hepatitis C virus; Immunosuppression; Liver transplantation

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 28B; RAPAMYCIN; VIRUS RNA; ANTIVIRUS AGENT;

ACUTE GRAFT REJECTION; AGE; CHRONIC GRAFT REJECTION; GENOTYPE; GRAFT FAILURE; GRAFT STEATOSIS; HEPATITIS C; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; ISCHEMIC PRECONDITIONING; LIVER GRAFT; LIVER TRANSPLANTATION; LIVING DONOR; MIXED INFECTION; POSTOPERATIVE PERIOD; RECURRENT DISEASE; REINFECTION; REPERFUSION INJURY; REVIEW; STEATOSIS; VIREMIA; ADVERSE EFFECTS; ANIMAL; COMPLICATION; DRUG EFFECTS; GENETICS; GRAFT REJECTION; GRAFT SURVIVAL; HEPACIVIRUS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; LIVER CIRRHOSIS; PATHOGENICITY; RISK FACTOR; TIME; TREATMENT OUTCOME; VIROLOGY; VIRUS ACTIVATION;

ANIMALS; ANTIVIRAL AGENTS; GRAFT REJECTION; GRAFT SURVIVAL; HEPACIVIRUS; HEPATITIS C; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; RECURRENCE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 84909609695     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i32.11095     Document Type: Review

References (201)

1. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1-S9 [PMID: 14586888 DOI: 10.1053/jlts.2003.50268]
2. Adam R, McMaster P, O'Grady JG, Castaing D, Klempnauer JL, Jamieson N, Neuhaus P, Lerut J, Salizzoni M, Pollard S, Muhlbacher F, Rogiers X, Garcia Valdecasas JC, Berenguer J, Jaeck D, Moreno Gonzalez E. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 2003; 9: 1231-1243 [PMID: 14625822 DOI: 10.1016/j.lts.2003.09.018]
3. Sugawara Y, Makuuchi M. Living donor liver transplantation to patients with hepatitis C virus cirrhosis. World J Gastroenterol 2006; 12: 4461-4465 [PMID: 16874855 DOI: 10.3748/wjg.v12.i28.4461]
4. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, Maertens G, Williams R. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815-820 [PMID: 8596547 DOI: 10.1056/NEJM199603283341302]
5. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002; 8: S14-S18 [PMID: 12362293 DOI: 10.1053/jlts.2002.35781]
6. Burra P. Hepatitis C. Semin Liver Dis 2009; 29: 53-65 [PMID: 19235659 DOI: 10.1055/s-0029-1192055]
7. Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M, Combs C, Fennessy S, Roberts JP, Ascher NL. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103: 317-322 [PMID: 1377143]
8. Rosen HR. Hepatitis C virus in the human liver transplantation model. Clin Liver Dis 2003; 7: 107-125 [PMID: 12691461 DOI: 10.1016/S1089-3261(02)00073-9]
9. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, Rimola A, Rodes J. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680-687 [PMID: 11870384 DOI: 10.1053/jhep.2002.31773]
10. Böker KH, Dalley G, Bahr MJ, Maschek H, Tillmann HL, Trautwein C, Oldhaver K, Bode U, Pichlmayr R, Manns MP. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 1997; 25: 203-210 [PMID: 8985291 DOI: 10.1002/hep.510250137]
11. Negro F, Giostra E, Krawczynski K, Quadri R, Rubbia-Brandt L, Mentha G, Colucci G, Perrin L, Hadengue A. Detection of intrahepatic hepatitis C virus replication by strand-specific semi-quantitative RT-PCR: preliminary application to the liver transplantation model. J Hepatol 1998; 29: 1-11 [PMID: 9696486 DOI: 10.1016/S0168-8278(98)80172-4]
12. Di Martino V, Saurini F, Samuel D, Gigou M, Dussaix E, Reynès M, Bismuth H, Féray C. Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation. Hepatology 1997; 26: 1343-1350 [PMID: 9362382 DOI: 10.1002/hep.510260537]
13. Petrovic LM, Villamil FG, Vierling JM, Makowka L, Geller SA. Comparison of histopathology in acute allograft rejection and recurrent hepatitis C infection after liver transplantation. Liver Transpl Surg 1997; 3: 398-406 [PMID: 9346770 DOI: 10.1002/lt.500030407]
14. Gane EJ, Naoumov NV, Qian KP, Mondelli MU, Maertens G, Portmann BC, Lau JY, Williams R. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110: 167-177 [PMID: 8536853 DOI: 10.1053/gast.1996.v110.pm8536853]
15. Gretch DR, Bacchi CE, Corey L, dela Rosa C, Lesniewski RR, Kowdley K, Gown A, Frank I, Perkins JD, Carithers RL. Persistent hepatitis C virus infection after liver transplantation: clinical and virological features. Hepatology 1995; 22: 1-9 [PMID: 7601397 DOI: 10.1002/hep.1840220102]
16. Vargas V, Krawczynski K, Castells L, Martinez N, Esteban J, Allende H, Esteban R, Guardia J. Recurrent hepatitis C virus infection after liver transplantation: immunohistochemical assessment of the viral antigen. Liver Transpl Surg 1998; 4: 320-327 [PMID: 9649647 DOI: 10.1002/lt.500040407]
17. Fukumoto T, Berg T, Ku Y, Bechstein WO, Knoop M, Lemmens HP, Lobeck H, Hopf U, Neuhaus P. Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions. Hepatology 1996; 24: 1351-1354 [PMID: 8938160 DOI: 10.1002/hep.510240606]
18. Rosen HR, Schwartz JM. Hepatitis C quasispecies and severity of recurrence: cause, consequence, or coincidence? Liver Transpl 2002; 8: 646-648 [PMID: 12089722 DOI: 10.1053/jlts.2002.0080646]
19. Chazouilleres O, Kim M, Combs C, Ferrell L, Bacchetti P, Roberts J, Ascher NL, Neuwald P, Wilber J, Urdea M. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994; 106: 994-999 [PMID: 8144005]
20. Freeman RB, Tran S, Lee YM, Rohrer RJ, Kaplan MM. Serum hepatitis C RNA titers after liver transplantation are not correlated with immunosuppression or hepatitis. Transplantation 1996; 61: 542-546 [PMID: 8610378 DOI: 10.1097/00007890-199602270-00005]
21. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, Batts K, Moreno-Luna L, Poterucha J, Burgart L, Wiesner R, Kremers W, Rosen C, Charlton MR. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000; 32: 1125-1130 [PMID: 11050065 DOI: 10.1053/jhep.2000.19340]
22. Shackel NA, Jamias J, Rahman W, Prakoso E, Strasser SI, Koorey DJ, Crawford MD, Verran DJ, Gallagher J, Mc- Caughan GW. Early high peak hepatitis C viral load levels independently predict hepatitis C-related liver failure postliver transplantation. Liver Transpl 2009; 15: 709-718 [PMID: 19562704 DOI: 10.1002/lt.21747]
23. Pal S, Sullivan DG, Kim S, Lai KK, Kae J, Cotler SJ, Carithers RL, Wood BL, Perkins JD, Gretch DR. Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism. Gastroenterology 2006; 130: 1107-1116 [PMID: 16618405 DOI: 10.1053/j.gastro.2005.12.039]
24. Powers KA, Ribeiro RM, Patel K, Pianko S, Nyberg L, Pockros P, Conrad AJ, McHutchison J, Perelson AS. Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl 2006; 12: 207-216 [PMID: 16447184 DOI: 10.1002/lt.20572]
25. Dahari H, Feliu A, Garcia-Retortillo M, Forns X, Neumann AU. Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation. J Hepatol 2005; 42: 491-498 [PMID: 15763335 DOI: 10.1016/j.jhep.2004.12.017]
26. Feliu A, Gay E, García-Retortillo M, Saiz JC, Forns X. Evolution of hepatitis C virus quasispecies immediately following liver transplantation. Liver Transpl 2004; 10: 1131-1139 [PMID: 15350003 DOI: 10.1002/lt.20206]
27. Gray RR, Strickland SL, Veras NM, Goodenow MM, Pybus OG, Lemon SM, Fried MW, Nelson DR, Salemi M. Unexpected maintenance of hepatitis C viral diversity following liver transplantation. J Virol 2012; 86: 8432-8439 [PMID: 22623804 DOI: 10.1128/JVI.00749-12]
28. Hughes MG, Chong TW, Smith RL, Evans HL, Iezzoni JC, Sawyer RG, Rudy CK, Pruett TL. HCV infection of the transplanted liver: changing CD81 and HVR1 variants immediately after liver transplantation. Am J Transplant 2005; 5: 2504-2513 [PMID: 16162201 DOI: 10.1111/j.1600-6143.2005.01060.x]
29. Krieger M. Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. J Clin Invest 2001; 108: 793-797 [PMID: 11560945 DOI: 10.1172/JCI14011]
30. Maillard P, Huby T, Andréo U, Moreau M, Chapman J, Budkowska A. The interaction of natural hepatitis C virus with human scavenger receptor SR-BI/Cla1 is mediated by ApoB-containing lipoproteins. FASEB J 2006; 20: 735-737 [PMID: 16476701 DOI: 10.1096/fj.05-4728fje]
31. Hishiki T, Shimizu Y, Tobita R, Sugiyama K, Ogawa K, Funami K, Ohsaki Y, Fujimoto T, Takaku H, Wakita T, Baumert TF, Miyanari Y, Shimotohno K. Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms. J Virol 2010; 84: 12048-12057 [PMID: 20826689 DOI: 10.1128/JVI.01063-10]
32. Meuleman P, Catanese MT, Verhoye L, Desombere I, Farhoudi A, Jones CT, Sheahan T, Grzyb K, Cortese R, Rice CM, Leroux-Roels G, Nicosia A. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology 2012; 55: 364-372 [PMID: 21953761 DOI: 10.1002/hep.24692]
33. Fafi-Kremer S, Fofana I, Soulier E, Carolla P, Meuleman P, Leroux-Roels G, Patel AH, Cosset FL, Pessaux P, Doffoël M, Wolf P, Stoll-Keller F, Baumert TF. Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med 2010; 207: 2019-2031 [PMID: 20713596 DOI: 10.1084/jem.20090766]
34. Sullivan DG, Wilson JJ, Carithers RL, Perkins JD, Gretch DR. Multigene tracking of hepatitis C virus quasispecies after liver transplantation: correlation of genetic diversification in the envelope region with asymptomatic or mild disease patterns. J Virol 1998; 72: 10036-10043 [PMID: 9811742]
35. Pessoa MG, Bzowej N, Berenguer M, Phung Y, Kim M, Ferrell L, Hassoba H, Wright TL. Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. Hepatology 1999; 30: 1513-1520 [PMID: 10573532 DOI: 10.1002/hep.510300610]
36. Gretch DR, Polyak SJ, Wilson JJ, Carithers RL, Perkins JD, Corey L. Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients. J Virol 1996; 70: 7622-7631 [PMID: 8892882]
37. Doughty AL, Painter DM, McCaughan GW. Post-transplant quasispecies pattern remains stable over time in patients with recurrent cholestatic hepatitis due to hepatitis C virus. J Hepatol 2000; 32: 126-134 [PMID: 10673077 DOI: 10.1016/S0168-8278(00)80199-3]
38. Vargas HE, Laskus T, Wang LF, Lee R, Radkowski M, Dodson F, Fung JJ, Rakela J. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology 1999; 117: 149-153 [PMID: 10381921 DOI: 10.1016/S0016-5085(99)70561-5]
39. Féray C, Gigou M, Samuel D, Paradis V, Mishiro S, Maertens G, Reynés M, Okamoto H, Bismuth H, Bréchot C. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995; 108: 1088-1096 [PMID: 7698576 DOI: 10.1016/0016-5085(95)90207-4]
40. Pageaux GP, Ducos J, Mondain AM, Costes V, Picot MC, Perrigault PF, Domergue J, Larrey D, Michel H. Hepatitis C virus genotypes and quantitation of serum hepatitis C virus RNA in liver transplant recipients: relationship with severity of histological recurrence and implications in the pathogenesis of HCV infection. Liver Transpl Surg 1997; 3: 501-505 [PMID: 9346792 DOI: 10.1002/lt.500030504]
41. Féray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T, Loinaz C, Gigou M, Burra P, Barkholt L, Esteban R, Bizollon T, Lerut J, Minello-Franza A, Bernard PH, Nachbaur K, Botta-Fridlund D, Bismuth H, Schalm SW, Samuel D. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999; 117: 619-625 [PMID: 10464137 DOI: 10.1016/S0016-5085(99)70454-3]
42. Gayowski T, Singh N, Marino IR, Vargas H, Wagener M, Wannstedt C, Morelli F, Laskus T, Fung JJ, Rakela J, Starzl TE. Hepatitis C virus genotypes in liver transplant recipients: impact on posttransplant recurrence, infections, response to interferon-alpha therapy and outcome. Transplantation 1997; 64: 422-426 [PMID: 9275107 DOI: 10.1097/00007890-199708150-00009]
43. Humar A, Kumar D, Raboud J, Caliendo AM, Moussa G, Levy G, Mazzulli T. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant 2002; 2: 461-466 [PMID: 12123213 DOI: 10.1034/j.1600-6143.2002.20511.x]
44. Singh N, Husain S, Carrigan DR, Knox KK, Weck KE, Wagener MM, Gayowski T. Impact of human herpesvirus-6 on the frequency and severity of recurrent hepatitis C virus hepatitis in liver transplant recipients. Clin Transplant 2002; 16: 92-96 [PMID: 11966777 DOI: 10.1034/j.1399-0012.2002.1o096.x]
45. Bosch W, Heckman MG, Pungpapong S, Diehl NN, Shalev JA, Hellinger WC. Association of cytomegalovirus infection and disease with recurrent hepatitis C after liver transplantation. Transplantation 2012; 93: 723-728 [PMID: 22406819 DOI: 10.1097/TP.0b013e3182472876]
46. Nebbia G, Mattes FM, Cholongitas E, Garcia-Diaz A, Samonakis DN, Burroughs AK, Emery VC. Exploring the bidirectional interactions between human cytomegalovirus and hepatitis C virus replication after liver transplantation. Liver Transpl 2007; 13: 130-135 [PMID: 17192909 DOI: 10.1002/lt.21037]
47. Terrault NA, Dailey PJ, Ferrell L, Collins ML, Wilber JC, Urdea MS, Bhandari BN, Wright TL. Hepatitis C virus: quantitation and distribution in liver. J Med Virol 1997; 51: 217-224 [PMID: 9139087 DOI: 10.1002/(SICI)1096-9071(199703)51]
48. Ballardini G, De Raffele E, Groff P, Bioulac-Sage P, Grassi A, Ghetti S, Susca M, Strazzabosco M, Bellusci R, Iemmolo RM, Grazi G, Zauli D, Cavallari A, Bianchi FB. Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver. Liver Transpl 2002; 8: 10-20 [PMID: 11799480 DOI: 10.1053/jlts.2002.30141]
49. Grassi A, Quarneti C, Ravaioli M, Bianchini F, Susca M, D'Errico A, Piscaglia F, Tamè MR, Andreone P, Grazi G, Galli S, Zauli D, Pinna AD, Bianchi FB, Ballardini G. Detection of HCV antigens in liver graft: relevance to the management of recurrent post-liver transplant hepatitis C. Liver Transpl 2006; 12: 1673-1681 [PMID: 17031825 DOI: 10.1002/lt.20882]
50. Mensa L, Pérez-del-Pulgar S, Crespo G, Koutsoudakis G, Fernández-Carrillo C, Coto-Llerena M, Miquel R, Allende H, Castells L, Navasa M, Forns X. Imaging of hepatitis C virus infection in liver grafts after liver transplantation. J Hepatol 2013; 59: 271-278 [PMID: 23548198 DOI: 10.1016/j.jhep.2013.03.023]
51. Ferrell LD, Wright TL, Roberts J, Ascher N, Lake J. Hepatitis C viral infection in liver transplant recipients. Hepatology 1992; 16: 865-876 [PMID: 1383115 DOI: 10.1002/hep.1840160403]
52. Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, Kolesnikov V, Bodenheimer H, Emre S, Miller CM. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 30-34 [PMID: 7806166 DOI: 10.1002/hep.1840210107]
53. Greenson JK, Svoboda-Newman SM, Merion RM, Frank TS. Histologic progression of recurrent hepatitis C in liver transplant allografts. Am J Surg Pathol 1996; 20: 731-738 [PMID: 8651353]
54. Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, Holt C, Lewin KJ, Busuttil RW, Martin P. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997; 92: 1453-1457 [PMID: 9317061]
55. Younossi ZM, Boparai N, Gramlich T, Goldblum J, George P, Mayes J. Agreement in pathologic interpretation of liver biopsy specimens in posttransplant hepatitis C infection. Arch Pathol Lab Med 1999; 123: 143-145 [PMID: 10050788]
56. Regev A, Molina E, Moura R, Bejarano PA, Khaled A, Ruiz P, Arheart K, Berho M, Drachenberg CB, Mendez P, O'Brien C, Jeffers L, Tzakis A, Schiff ER. Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation. Liver Transpl 2004; 10: 1233-1239 [PMID: 15376303 DOI: 10.1002/lt.20245]
57. Sadamori H, Yagi T, Iwagaki H, Matsuda H, Shinoura S, Umeda Y, Ohara N, Yanai H, Ogino T, Tanaka N. Immunohistochemical staining of liver grafts with a monoclonal antibody against HCV-Envelope 2 for recurrent hepatitis C after living donor liver transplantation. J Gastroenterol Hepatol 2009; 24: 574-580 [PMID: 19368635 DOI: 10.1111/j.1440-1746.2008.05638.x]
58. D'Errico-Grigioni A, Fiorentino M, Vasuri F, Gruppioni E, Fabbrizio B, Zucchini N, Ballardini G, Morelli C, Pinna AD, Grigioni WF. Tissue hepatitis C virus RNA quantification and protein expression help identify early hepatitis C virus recurrence after liver transplantation. Liver Transpl 2008; 14: 313-320 [PMID: 18306349 DOI: 10.1002/lt.21375]
59. Vasuri F, Morelli MC, Gruppioni E, Fiorentino M, Ercolani G, Cescon M, Pinna AD, Grigioni WF, D'Errico-Grigioni A. The meaning of tissue and serum HCV RNA quantitation in hepatitis C recurrence after liver transplantation: a retrospective study. Dig Liver Dis 2013; 45: 505-509 [PMID: 23317815 DOI: 10.1016/j.dld.2012.11.015]
60. Ciccorossi P, Filipponi F, Oliveri F, Campani D, Colombatto P, Bonino F, Campa M, Maltinti G, Mosca F, Brunetto MR. Increasing serum levels of IgM anti-HCV are diagnostic of recurrent hepatitis C in liver transplant patients with ALT flares. J Viral Hepat 2003; 10: 168-173 [PMID: 12753334 DOI: 10.1046/j.1365-2893.2003.00425.x]
61. Schmeding M, Dankof A, Krenn V, Krukemeyer MG, Koch M, Spinelli A, Langrehr JM, Neumann UP, Neuhaus P. C4d in acute rejection after liver transplantation - a valuable tool in differential diagnosis to hepatitis C recurrence. Am J Transplant 2006; 6: 523-530 [PMID: 16468961 DOI: 10.1111/j.1600-6143.2005.01180.x]
62. Schmeding M, Kienlein S, Röcken C, Neuhaus R, Neuhaus P, Heidenhain C, Neumann UP. ELISA-based detection of C4d after liver transplantation - a helpful tool for differential diagnosis between acute rejection and HCV-recurrence? Transpl Immunol 2010; 23: 156-160 [PMID: 20558292 DOI: 10.1016/j.trim.2010.06.002]
63. Asaoka T, Kato T, Marubashi S, Dono K, Hama N, Takahashi H, Kobayashi S, Takeda Y, Takemasa I, Nagano H, Yoshida H, Ruiz P, Tzakis AG, Matsubara K, Monden M, Doki Y, Mori M. Differential transcriptome patterns for acute cellular rejection in recipients with recurrent hepatitis C after liver transplantation. Liver Transpl 2009; 15: 1738-1749 [PMID: 19938108 DOI: 10.1002/lt.21883]
64. Joshi D, Salehi S, Brereton H, Arno M, Quaglia A, Heaton N, O'Grady J, Agarwal K, Aluvihare V. Distinct microRNA profiles are associated with the severity of hepatitis C virus recurrence and acute cellular rejection after liver transplantation. Liver Transpl 2013; 19: 383-394 [PMID: 23408392 DOI: 10.1002/lt.23613]
65. Cabrera R, Ararat M, Soldevila-Pico C, Dixon L, Pan JJ, Firpi R, Machicao V, Levy C, Nelson D, Morelli G. Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients. Liver Transpl 2009; 15: 216-222 [PMID: 19177434 DOI: 10.1002/lt.21666]
66. Donaldson PT, Alexander GJ, O'Grady J, Neuberger J, Portmann B, Thick M, Davis H, Calne RY, Williams R. Evidence for an immune response to HLA class I antigens in the vanishing-bileduct syndrome after liver transplantation. Lancet 1987; 1: 945-951 [PMID: 2882341 DOI: 10.1016/S0140-6736(87)90293-5]
67. Yagihashi A, Kobayashi M, Noguchi K, Konno A, Yoshida Y, Terasawa K, Starzl TE, Iwaki Y. HLA matching effect in liver transplantation. Transplant Proc 1992; 24: 2432-2433 [PMID: 1281569]
68. Thorogood J. Relationship between HLA compatibility and first liver allograft survival. l'ESPRIT Study Group. Transplant Proc 1993; 25: 2655-2656 [PMID: 8356710]
69. Mañez R, Mateo R, Tabasco J, Kusne S, Starzl TE, Duquesnoy RJ. The influence of HLA donor-recipient compatibility on the recurrence of HBV and HCV hepatitis after liver transplantation. Transplantation 1995; 59: 640-642 [PMID: 7878772 DOI: 10.1097/00007890-199559040-00036]
70. Langrehr JM, Puhl G, Bahra M, Schmeding M, Spinelli A, Berg T, Schönemann C, Krenn V, Neuhaus P, Neumann UP. Influence of donor/recipient HLA-matching on outcome and recurrence of hepatitis C after liver transplantation. Liver Transpl 2006; 12: 644-651 [PMID: 16555324 DOI: 10.1002/lt.20648]
71. Rosen HR, Hinrichs DJ, Leistikow RL, Callender G, Wertheimer AM, Nishimura MI, Lewinsohn DM. Cutting edge: identification of hepatitis C virus-specific CD8+ T cells restricted by donor HLA alleles following liver transplantation. J Immunol 2004; 173: 5355-5359 [PMID: 15494481]
72. Belli LS, Burra P, Poli F, Battista Alberti A, Silini E, Zavaglia C, Fagiuoli S, Prando D, Espadas de Arias A, Boninsegna S, Tinelli C, Scalamogna M, de Carlis L, Pinzello G. HLA-DRB1 donor-recipient mismatch affects the outcome of hepatitis C disease recurrence after liver transplantation. Gastroenterology 2006; 130: 695-702 [PMID: 16530511 DOI: 10.1053/j.gastro.2005.11.013]
73. Balan V, Ruppert K, Demetris AJ, Ledneva T, Duquesnoy RJ, Detre KM, Wei YL, Rakela J, Schafer DF, Roberts JP, Everhart JE, Wiesner RH. Long-term outcome of human leukocyte antigen mismatching in liver transplantation: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Hepatology 2008; 48: 878-888 [PMID: 18752327 DOI: 10.1002/hep.22435]
74. Audet M, Piardi T, Cag M, Navarro F, Ornis S, Cinqualbre J, Wolf P, Panaro F. Hepatitis C recurrence after liver transplantation: has the human leukocyte antigen mismatching at individual loci a role? J Gastroenterol Hepatol 2011; 26: 1772-1778 [PMID: 22097939 DOI: 10.1111/j.1440-1746.2011.06772.x]
75. Berenguer M, Rayón JM, Prieto M, Aguilera V, Nicolás D, Ortiz V, Carrasco D, López-Andujar R, Mir J, Berenguer J. Are posttransplantation protocol liver biopsies useful in the long term? Liver Transpl 2001; 7: 790-796 [PMID: 11552213 DOI: 10.1053/jlts.2001.23794]
76. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401 [PMID: 19684573 DOI: 10.1038/nature08309]
77. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801 [PMID: 19759533 DOI: 10.1038/nature08463]
78. Duarte-Rojo A, Deneke MG, Charlton MR. Interleukin-28B polymorphism in hepatitis C and liver transplantation. Liver Transpl 2013; 19: 49-58 [PMID: 23008132 DOI: 10.1002/lt.23554]
79. Duarte-Rojo A, Veldt BJ, Goldstein DD, Tillman HL, Watt KD, Heimbach JK, McHutchison JG, Poterucha JJ, Vargas- Vorackova F, Charlton MR. The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation 2012; 94: 197-203 [PMID: 22766768 DOI: 10.1097/TP.0b013e3182547551]
80. Chin JL, Nicholas RM, Russell J, Carr M, Connell J, Stewart S, McCormick PA. Spontaneous clearance of hepatitis C infection after liver transplantation from IL28B rs12979860 CC donors. Eur J Gastroenterol Hepatol 2012; 24: 1110-1112 [PMID: 22664940 DOI: 10.1097/MEG.0b013e3283554291]
81. Biggins SW, Trotter J, Gralla J, Burton JR, Bambha KM, Dodge J, Brocato M, Cheng L, McQueen M, Forman L, Chang M, Kam I, Everson G, Spritz RA, Klintmalm G, Rosen HR. Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation. J Hepatol 2013; 58: 969-976 [PMID: 23333445 DOI: 1016/j.jhep.2012.12.027]
82. Bitetto D, Fabris C, Falleti E, Fornasiere E, Avellini C, Cmet S, Cussigh A, Fontanini E, Pirisi M, Corradini SG, Merli M, Molinaro A, Toniutto P. Recipient interleukin-28B Rs12979860 C/T polymorphism and acute cellular rejection after liver transplantation: role of the calcineurin inhibitor used. Transplantation 2012; 93: 1038-1044 [PMID: 22495472 DOI: 10.1097/TP.0b013e31824df7f3]
83. Lange CM, Moradpour D, Doehring A, Lehr HA, Müllhaupt B, Bibert S, Bochud PY, Antonino AT, Pascual M, Farnik H, Shi Y, Bechstein WO, Moench C, Hansmann ML, Sarrazin C, Lötsch J, Zeuzem S, Hofmann WP. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol 2011; 55: 322-327 [PMID: 21147186 DOI: 10.1016/j.jhep.2010.10.037]
84. Eurich D, Boas-Knoop S, Ruehl M, Schulz M, Carrillo ED, Berg T, Neuhaus R, Neuhaus P, Neumann UP, Bahra M. Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transpl 2011; 17: 289-298 [PMID: 21384511 DOI: 10.1002/lt.22235]
85. Doughty AL, Spencer JD, Cossart YE, McCaughan GW. Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels. Liver Transpl Surg 1998; 4: 15-21 [PMID: 9457962]
86. Jain A, Menegus M, Mohanka R, Orloff M, Abt P, Mantry P, Bozorgzadeh A. HCV antibody quantitative levels in liver transplant patients: do they have any relevance in clinical practice? Exp Clin Transplant 2006; 4: 475-480 [PMID: 16827647]
87. Rehermann B, Chisari FV. Cell mediated immune response to the hepatitis C virus. Curr Top Microbiol Immunol 2000; 242: 299-325 [PMID: 10592666 DOI: 10.1007/978-3-642-59605-6-14]
88. Asanza CG, García-Monzón C, Clemente G, Salcedo M, García-Buey L, García-Iglesias C, Bañares R, Alvarez E, Moreno-Otero R. Immunohistochemical evidence of immunopathogenetic mechanisms in chronic hepatitis C recurrence after liver transplantation. Hepatology 1997; 26: 755-763 [PMID: 9303509 DOI: 10.1002/hep.510260331]
89. Rosen HR, Hinrichs DJ, Gretch DR, Koziel MJ, Chou S, Houghton M, Rabkin J, Corless CL, Bouwer HG. Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology 1999; 117: 926-932 [PMID: 10500076 DOI: 10.1016/S0016-5085(99)70352-5]
90. Schirren CA, Jung MC, Worzfeld T, Mamin M, Baretton G, Gerlach JT, Gruener NH, Zachoval R, Houghton M, Rau HG, Pape GR. Hepatitis C virus-specific CD4+ T cell response after liver transplantation occurs early, is multispecific, compartmentalizes to the liver, and does not correlate with recurrent disease. J Infect Dis 2001; 183: 1187-1194 [PMID: 11262200 DOI: 10.1086/319692]
91. Weston SJ, Leistikow RL, Reddy KR, Torres M, Wertheimer AM, Lewinsohn DM, Chou S, Davey MP, Corless C, O'Farrelly C, Nelson DR, Rosen HR. Reconstitution of hepatitis C virus-specific T-cellmediated immunity after liver transplantation. Hepatology 2005; 41: 72-81 [PMID: 15619226 DOI: 10.1002/hep.20507]
92. Mendler M, Kwok H, Franco E, Baron P, Weissman J, Ojogho O. Monitoring peripheral blood CD4+ adenosine triphosphate activity in a liver transplant cohort: insight into the interplay between hepatitis C virus infection and cellular immunity. Liver Transpl 2008; 14: 1313-1322 [PMID: 18756485 DOI: 10.1002/lt.21529]
93. Te HS, Dasgupta KA, Cao D, Satoskar R, Mohanty SR, Reau N, Millis JM, Jensen DM. Use of immune function test in monitoring immunosuppression in liver transplant recipients. Clin Transplant 2012; 26: 826-832 [PMID: 22554357 DOI: 10.1111/j.1399-0012.2012.01632]
94. Alkhouri N, Hanouneh IA, Lopez R, Zein NN. Monitoring peripheral blood CD4+ adenosine triphosphate activity in recurrent hepatitis C and its correlation to fibrosis progression. Liver Transpl 2010; 16: 155-162 [PMID: 20104483 DOI: 10.1002/lt.21939]
95. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T. Immunologic tolerance maintained by CD25+ CD4+ regula-tory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001; 182: 18-32 [PMID: 11722621 DOI: 10.1034/j.1600-065X.2001.1820102]
96. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-1164 [PMID: 7636184]
97. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002; 3: 135-142 [PMID: 11812990 DOI: 10.1038/ni759]
98. Carpentier A, Conti F, Stenard F, Aoudjehane L, Miroux C, Podevin P, Morales O, Chouzenoux S, Scatton O, Groux H, Auriault C, Calmus Y, Pancre V, Delhem N. Increased expression of regulatory Tr1 cells in recurrent hepatitis C after liver transplantation. Am J Transplant 2009; 9: 2102-2112 [PMID: 19624566 DOI: 10.1111/j.1600-6143.2009.02743]
99. Perrella A, Arenga G, Pisaniello D, Rampone B, Di Costanzo GG, Atripaldi L, Esposito C, Di Florio E, Perrella O, Cuomo O. Elevated CD4+/CD25+ T-cell frequency and function during hepatitis C virus recurrence after liver transplantation. Transplant Proc 2009; 41: 1761-1766 [PMID: 19545723 DOI: 10.1016/j.transproceed.2009.01.112]
100. Kanto T, Inoue M, Miyatake H, Sato A, Sakakibara M, Yakushijin T, Oki C, Itose I, Hiramatsu N, Takehara T, Kasahara A, Hayashi N. Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection. J Infect Dis 2004; 190: 1919-1926 [PMID: 15529255 DOI: 10.1086/425425]
101. Longman RS, Talal AH, Jacobson IM, Rice CM, Albert ML. Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C. J Infect Dis 2005; 192: 497-503 [PMID: 15995965 DOI: 10.1086/43152]
102. Ocaña L, Cos J, Quer J, Bilbao I, Palou E, Parra R, Sauleda S, Esteban JI, Guàrdia J, Massuet LI, Margarit C. Analysis of INF-gamma, TNF-alpha and dendritic cells to predict hepatitis C virus recurrence in liver transplant patients. Transplant Proc 2005; 37: 3951-3956 [PMID: 16386594 DOI: 10.1016/j.tra nsproceed.2005.09.183]
103. Schvoerer E, Thumann C, Spohrer S, Soulier E, Royer C, Brignon N, Doridot S, Meyer N, Ellero B, Woehl-Jaegle ML, Meyer C, Wolf P, Jaeck D, Stoll-Keller F. Early decrease in circulating dendritic cells number after liver transplantation could favor hepatitis C virus recurrence. J Med Virol 2006; 78: 1070-1075 [PMID: 16789017 DOI: 10.1002/jmv.20664]
104. Corado J, Toro F, Rivera H, Bianco NE, Deibis L, De Sanctis JB. Impairment of natural killer (NK) cytotoxic activity in hepatitis C virus (HCV) infection. Clin Exp Immunol 1997; 109: 451-457 [PMID: 9328121 DOI: 10.1046/j.1365-2249.1997.4581355]
105. Deignan T, Curry MP, Doherty DG, Golden-Mason L, Volkov Y, Norris S, Nolan N, Traynor O, McEntee G, Hegarty JE, O'Farrelly C. Decrease in hepatic CD56(+) T cells and V alpha 24(+) natural killer T cells in chronic hepatitis C viral infection. J Hepatol 2002; 37: 101-108 [PMID: 12076868 DOI: 10.1016/S0168-8278(02)00072-7]
106. Rosen HR, Doherty DG, Madrigal-Estebas L, O'Farrelly C, Golden-Mason L. Pretransplantation CD56(+) innate lymphocyte populations associated with severity of hepatitis C virus recurrence. Liver Transpl 2008; 14: 31-40 [PMID: 18161829 DOI: 10.1002/lt.21265]
107. Varchetta S, Oliviero B, Francesca Donato M, Agnelli F, Rigamonti C, Paudice E, Arosio E, Berra M, Rossi G, Tinelli C, Fagnoni FF, Colombo M, Mavilio D, Mondelli MU. Prospective study of natural killer cell phenotype in recurrent hepatitis C virus infection following liver transplantation. J Hepatol 2009; 50: 314-322 [PMID: 19070924 DOI: 10.1016/j.jhep.2008.10.018]
108. Howell J, Sawhney R, Skinner N, Gow P, Angus P, Ratnam D, Visvanathan K. Toll-like receptor 3 and 7/8 function is impaired in hepatitis C rapid fibrosis progression post-liver transplantation. Am J Transplant 2013; 13: 943-953 [PMID: 23425350 DOI: 10.1111/ajt.1216]
109. de Arias AE, Haworth SE, Belli LS, Burra P, Pinzello G, Vangeli M, Minola E, Guido M, Boccagni P, De Feo TM, Torelli R, Cardillo M, Scalamogna M, Poli F. Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation. Liver Transpl 2009; 15: 390-399 [PMID: 19326408 DOI: 10.1002/lt.21673]
110. Tambur AR, Ortegel JW, Ben-Ari Z, Shabtai E, Klein T, Michowiz R, Tur-Kaspa R, Mor E. Role of cytokine gene polymorphism in hepatitis C recurrence and allograft rejection among liver transplant recipients. Transplantation 2001; 71: 1475-1480 [PMID: 11391238 DOI: 10.1097/00007890-200105270-00020]
111. Nagai S, Yoshida A, Kohno K, Altshuler D, Nakamura M, Brown KA, Abouljoud MS, Moonka D. Peritransplant absolute lymphocyte count as a predictive factor for advanced recurrence of hepatitis C after liver transplantation. Hepatology 2014; 59: 35-45 [PMID: 23728831 DOI: 10.1002/hep.26536]
112. Berg T, Müller AR, Platz KP, Höhne M, Bechstein WO, Hopf U, Wiedenmann B, Neuhaus P, Schreier E. Dynamics of GB virus C viremia early after orthotopic liver transplantation indicates extrahepatic tissues as the predominant site of GB virus C replication. Hepatology 1999; 29: 245-249 [PMID: 9862873]
113. Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl 2003; 9: S63-S66 [PMID: 14586898 DOI: 10.1053/jlts.2003.50264]
114. Samuel D, Forns X, Berenguer M, Trautwein C, Burroughs A, Rizzetto M, Trepo C. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol 2006; 45: 127-143 [PMID: 16723165 DOI: 10.1016/j.jhep.2006.05.001]
115. Ciesek S, Steinmann E, Iken M, Ott M, Helfritz FA, Wappler I, Manns MP, Wedemeyer H, Pietschmann T. Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology 2010; 138: 1875-1884 [PMID: 20152835 DOI: 10.1053/j.gastro.2010.02.004]
116. Boor PP, Metselaar HJ, Mancham S, Tilanus HW, Kusters JG, Kwekkeboom J. Prednisolone suppresses the function and promotes apoptosis of plasmacytoid dendritic cells. Am J Transplant 2006; 6: 2332-2341 [PMID: 16889610 DOI: 10.1111/j.1600-6143.2006.01476]
117. Klintmalm GB, Washburn WK, Rudich SM, Heffron TG, Teperman LW, Fasola C, Eckhoff DE, Netto GJ, Katz E. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007; 13: 1521-1531 [PMID: 17969201 DOI: 10.1002/lt.21182]
118. Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, Pomfret EA, Vargas HE, Brown R, Eckhoff D, Pruett TL, Roberts J, Mulligan DC, Charlton MR, Heffron TG, Ham JM, Douglas DD, Sher L, Baliga PK, Kinkhabwala M, Koneru B, Abecassis M, Millis M, Jennings LW, Fasola CG. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl 2011; 17: 1394-1403 [PMID: 21850690 DOI: 10.1002/lt.22417]
119. Kato T, Gaynor JJ, Yoshida H, Montalvano M, Takahashi H, Pyrsopoulos N, Nishida S, Moon J, Selvaggi G, Levi D, Ruiz P, Schiff E, Tzakis A. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. Transplantation 2007; 84: 829-835 [PMID: 17984834 DOI: 10.1097/01.tp.0000282914.20578.7b]
120. Lladó L, Fabregat J, Castellote J, Ramos E, Xiol X, Torras J, Serrano T, Baliellas C, Figueras J, Garcia-Gil A, Rafecas A. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study. Liver Transpl 2008; 14: 1752-1760 [PMID: 19025919 DOI: 10.1002/lt.21629]
121. Manousou P, Samonakis D, Cholongitas E, Patch D, O'Beirne J, Dhillon AP, Rolles K, McCormick A, Hayes P, Burroughs AK. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transpl 2009; 15: 1783-1791 [PMID: 19938143 DOI: 10.1002/lt.21907]
122. Weiler N, Thrun I, Hoppe-Lotichius M, Zimmermann T, Kraemer I, Otto G. Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial. Transplantation 2010; 90: 1562-1566 [PMID: 21048536 DOI: 10.1097/TP.0b013e3181ff8794]
123. Neumann U, Samuel D, Trunečka P, Gugenheim J, Gerunda GE, Friman S. A Randomized Multicenter Study Comparing a Tacrolimus-Based Protocol with and without Steroids in HCV-Positive Liver Allograft Recipients. J Transplant 2012; 2012: 894215 [PMID: 22690326 DOI: 10.1155/2012/894215]
124. Brillanti S, Vivarelli M, De Ruvo N, Aden AA, Camaggi V, D'Errico A, Furlini G, Bellusci R, Roda E, Cavallari A. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002; 8: 884-888 [PMID: 12360428 DOI: 10.1053/jlts.2002.34640]
125. Vivarelli M, Burra P, La Barba G, Canova D, Senzolo M, Cucchetti A, D'Errico A, Guido M, Merenda R, Neri D, Zanello M, Giannini FM, Grazi GL, Cillo U, Pinna AD. Influence of steroids on HCV recurrence after liver transplantation: A prospective study. J Hepatol 2007; 47: 793-798 [PMID: 17928091 DOI: 10.1016/j.jhep.2007.07.023]
126. Segev DL, Sozio SM, Shin EJ, Nazarian SM, Nathan H, Thuluvath PJ, Montgomery RA, Cameron AM, Maley WR. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl 2008; 14: 512-525 [PMID: 18383081 DOI: 10.1002/lt.21396]
127. National Institutes of Health. Liver Transplantation. Consensus Development Conference Summary. Washington, DC: NIH Consens Statement Online, 1983: 1-15
128. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 1282-1288 [PMID: 14578868 DOI: 10.1053/jhep.2003.50449]
129. Nakagawa M, Sakamoto N, Tanabe Y, Koyama T, Itsui Y, Takeda Y, Chen CH, Kakinuma S, Oooka S, Maekawa S, Enomoto N, Watanabe M. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology 2005; 129: 1031-1041 [PMID: 16143140 DOI: 10.1053/j.gastro.2005.06.031]
130. Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007; 13: 21-29 [PMID: 17192906 DOI: 10.1002/lt.21035]
131. Irish WD, Arcona S, Bowers D, Trotter JF. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. Am J Transplant 2011; 11: 1676-1685 [PMID: 21564522 DOI: 10.1111/j.1600-6143.2011.03508]
132. Henry SD, Metselaar HJ, Lonsdale RC, Kok A, Haagmans BL, Tilanus HW, van der Laan LJ. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology 2006; 131: 1452-1462 [PMID: 17101321 DOI: 10.1053/j.gastro.2006.08.027]
133. Pan Q, de Ruiter PE, Metselaar HJ, Kwekkeboom J, de Jonge J, Tilanus HW, Janssen HL, van der Laan LJ. Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo. Hepatology 2012; 55: 1673-1683 [PMID: 22213147 DOI: 10.1002/hep.25562]
134. Schlitt HJ, Barkmann A, Böker KH, Schmidt HH, Emmanouilidis N, Rosenau J, Bahr MJ, Tusch G, Manns MP, Nashan B, Klempnauer J. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001; 357: 587-591 [PMID: 11558484 DOI: 10.1016/S0140-6736(00)04055-1]
135. Stewart SF, Hudson M, Talbot D, Manas D, Day CP. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001; 357: 609-610 [PMID: 11558493 DOI: 10.1016/S0140-6736(00)04065-4]
136. Germani G, Pleguezuelo M, Villamil F, Vaghjiani S, Tsochatzis E, Andreana L, Burroughs AK. Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil. Am J Transplant 2009; 9: 1725-1731 [PMID: 19538488 DOI: 10.1111/j.1600-6143.2009.02705]
137. Manzia TM, Angelico R, Toti L, Bellini MI, Sforza D, Palmieri G, Orlando G, Tariciotti L, Angelico M, Tisone G. Longterm, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C. Transpl Int 2011; 24: 461-468 [PMID: 21294787 DOI: 10.1111/j.1432-2277.2011.01228]
138. Coito C, Diamond DL, Neddermann P, Korth MJ, Katze MG. High-throughput screening of the yeast kinome: identification of human serine/threonine protein kinases that phosphorylate the hepatitis C virus NS5A protein. J Virol 2004; 78: 3502-3513 [PMID: 15016873 DOI: 10.1128/JVI.78.7.3502-3513.2004]
139. Mannová P, Beretta L. Activation of the N-Ras-PI3K-Akt-mTOR pathway by hepatitis C virus: control of cell survival and viral replication. J Virol 2005; 79: 8742-8749 [PMID: 15994768 DOI: 10.1128/JVI.79.14.8742-8749.2005]
140. Wagner D, Kniepeiss D, Schaffellner S, Jakoby E, Mueller H, Fahrleitner-Pammer A, Stiegler P, Tscheliessnigg KH, Iberer F. Sirolimus has a potential to influent viral recurrence in HCV positive liver transplant candidates. Int Immunopharmacol 2010; 10: 990-993 [PMID: 20483386 DOI: 10.1016/j.intimp.2010.05.006]
141. Asthana S, Toso C, Meeberg G, Bigam DL, Mason A, Shapiro J, Kneteman NM. The impact of sirolimus on hepatitis C recurrence after liver transplantation. Can J Gastroenterol 2011; 25: 28-34 [PMID: 21258665]
142. McKenna GJ, Trotter JF, Klintmalm E, Onaca N, Ruiz R, Jennings LW, Neri M, O'Leary JG, Davis GL, Levy MF, Goldstein RM, Klintmalm GB. Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. Am J Transplant 2011; 11: 2379-2387 [PMID: 21967703 DOI: 10.1111/j.1600-6143.2011.03767]
143. Trotter JF. Hot-topic debate on hepatitis C virus: the type of immunosuppression matters. Liver Transpl 2011; 17 Suppl 3: S20-S23 [PMID: 21850693 DOI: 10.1002/lt.22414]
144. Watt KD, Dierkhising R, Heimbach JK, Charlton MR. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl 2012; 18: 1029-1036 [PMID: 22641474 DOI: 10.1002/lt.23479]
145. Marcos A, Eghtesad B, Fung JJ, Fontes P, Patel K, Devera M, Marsh W, Gayowski T, Demetris AJ, Gray EA, Flynn B, Zeevi A, Murase N, Starzl TE. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 2004; 78: 966-971 [PMID: 15480160 DOI: 10.1097/01.TP.0000142674.78268.01]
146. Eason JD, Loss GE, Blazek J, Nair S, Mason AL. Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial. Liver Transpl 2001; 7: 693-697 [PMID: 11510013 DOI: 10.1053/jlts.2001.26353]
147. Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003; 75: 1396-1399 [PMID: 12717237 DOI: 10.1097/01.TP.0000062834.30922.FE]
148. Tector AJ, Fridell JA, Mangus RS, Shah A, Milgrom M, Kwo P, Chalasani N, Yoo H, Rouch D, Liangpunsakul S, Herring S, Lumeng L. Promising early results with immunosuppression using rabbit anti-thymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients. Liver Transpl 2004; 10: 404-407 [PMID: 15004768 DOI: 10.1002/lt.20085]
149. Horton PJ, Tchervenkov J, Barkun JS, Rochon C, Chaudhury PK, Znajda TL, Martinie JB, Metrakos P. Antithymocyte globulin induction therapy in hepatitis C-positive liver transplant recipients. J Gastrointest Surg 2005; 9: 896-902 [PMID: 16137581 DOI: 10.1016/j.gassur.2005.06.020]
150. Nair S, Loss GE, Cohen AJ, Eason JD. Induction with rabbit antithymocyte globulin versus induction with corticosteroids in liver transplantation: impact on recurrent hepatitis C virus infection. Transplantation 2006; 81: 620-622 [PMID: 16495812 DOI: 10.1097/01.tp.0000181192.13836.8c]
151. De Ruvo N, Cucchetti A, Lauro A, Masetti M, Cautero N, Di Benedetto F, Dazzi A, Del Gaudio M, Ravaioli M, Di Francesco F, Molteni G, Ramacciato G, Risaliti A, Pinna AD. Preliminary results of a "prope" tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in liver transplantation. Transplantation 2005; 80: 8-12 [PMID: 16003226 DOI: 10.1097/01.TP.0000164349.54297.95]
152. Uemura T, Schaefer E, Hollenbeak CS, Khan A, Kadry Z. Outcome of induction immunosuppression for liver transplantation comparing anti-thymocyte globulin, daclizumab, and corticosteroid. Transpl Int 2011; 24: 640-650 [PMID: 21429047 DOI: 10.1111/j.1432-2277.2011.01250]
153. Nelson DR, Soldevila-Pico C, Reed A, Abdelmalek MF, Hemming AW, Van der Werf WJ, Howard R, Davis GL. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001; 7: 1064-1070 [PMID: 11753908 DOI: 10.1053/jlts.2001.29414]
154. Yoshizawa A, Takada Y, Fujimoto Y, Koshiba T, Haga H, Nabeshima S, Uemoto S. Liver transplantation from an identical twin without immunosuppression, with early recurrence of hepatitis C. Am J Transplant 2006; 6: 2812-2816 [PMID: 16939511 DOI: 10.1111/j.1600-143.2006.01531]
155. Orlando G, Soker S, Wood K. Operational tolerance after liver transplantation. J Hepatol 2009; 50: 1247-1257 [PMID: 19394103 DOI: 10.1016/j.jhep.2009.03.006]
156. Manzia TM, Angelico R, Toti L, Lai Q, Ciano P, Angelico M, Tisone G. Hepatitis C virus recurrence and immunosuppression-free state after liver transplantation. Expert Rev Clin Immunol 2012; 8: 635-644 [PMID: 23078061 DOI: 10.1586/eci.12.66]
157. Manzia TM, Angelico R, Baiocchi L, Toti L, Ciano P, Palmieri G, Angelico M, Orlando G, Tisone G. The Tor Vergata weaning of immunosuppression protocols in stable hepatitis C virus liver transplant patients: the 10-year follow-up. Transpl Int 2013; 26: 259-266 [PMID: 23278973 DOI: 10.1111/tri.12023]
158. Ohira M, Ishiyama K, Tanaka Y, Doskali M, Igarashi Y, Tashiro H, Hiraga N, Imamura M, Sakamoto N, Asahara T, Chayama K, Ohdan H. Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. J Clin Invest 2009; 119: 3226-3235 [PMID: 19805910 DOI: 10.1172/JCI38374]
159. Gurusamy KS, Tsochatzis E, Davidson BR, Burroughs AK. Antiviral prophylactic intervention for chronic hepatitis C virus in patients undergoing liver transplantation. Cochrane Database Syst Rev 2010; (12): CD006573 [PMID: 21154370 DOI: 10.1002/14651858.CD006573.pub2]
160. Chung RT, Gordon FD, Curry MP, Schiano TD, Emre S, Corey K, Markmann JF, Hertl M, Pomposelli JJ, Pomfret EA, Florman S, Schilsky M, Broering TJ, Finberg RW, Szabo G, Zamore PD, Khettry U, Babcock GJ, Ambrosino DM, Leav B, Leney M, Smith HL, Molrine DC. Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. Am J Transplant 2013; 13: 1047-1054 [PMID: 23356386 DOI: 10.1111/ajt.12083]
161. Gaglio PJ, Malireddy S, Levitt BS, Lapointe-Rudow D, Lefkowitch J, Kinkhabwala M, Russo MW, Emond JC, Brown RS. Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl 2003; 9: 1028-1035 [PMID: 14526396 DOI: 10.1053/jlts.2003.50211]
162. Thuluvath PJ, Yoo HY. Graft and patient survival after adult live donor liver transplantation compared to a matched cohort who received a deceased donor transplantation. Liver Transpl 2004; 10: 1263-1268 [PMID: 15376301 DOI: 10.1002/lt.20254]
163. Garcia-Retortillo M, Forns X, Llovet JM, Navasa M, Feliu A, Massaguer A, Bruguera M, Fuster J, Garcia-Valdecasas JC, Rimola A. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004; 40: 699-707 [PMID: 15349910 DOI: 10.1002/hep.20357]
164. Everson GT, Trotter J. Role of adult living donor liver transplantation in patients with hepatitis C. Liver Transpl 2003; 9: S64-S68 [PMID: 14528432 DOI: 10.1053/jlts.2003.50224]
165. Olthoff KM. Hepatic regeneration in living donor liver transplantation. Liver Transpl 2003; 9: S35-S41 [PMID: 14528426 DOI: 10.1053/jlts.2003.50229]
166. Zimmerman MA, Trotter JF. Living donor liver transplantation in patients with hepatitis C. Liver Transpl 2003; 9: S52-S57 [PMID: 14586896 DOI: 10.1053/jlts.2003.50256]
167. Shiffman ML, Stravitz RT, Contos MJ, Mills AS, Sterling RK, Luketic VA, Sanyal AJ, Cotterell A, Maluf D, Posner MP, Fisher RA. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl 2004; 10: 1248-1255 [PMID: 15376308 DOI: 10.1002/lt.20232]
168. Humar A, Horn K, Kalis A, Glessing B, Payne WD, Lake J. Living donor and split-liver transplants in hepatitis C recipients: does liver regeneration increase the risk for recurrence? Am J Transplant 2005; 5: 399-405 [PMID: 15644001 DOI: 10.1111/j.1600-6143.2004.00704]
169. Guo L, Orrego M, Rodriguez-Luna H, Balan V, Byrne T, Chopra K, Douglas DD, Harrison E, Moss A, Reddy KS, Williams JW, Rakela J, Mulligan D, Vargas HE. Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients. Liver Transpl 2006; 12: 560-565 [PMID: 16555313 DOI: 10.1002/lt.20660]
170. Terrault NA, Shiffman ML, Lok AS, Saab S, Tong L, Brown RS, Everson GT, Reddy KR, Fair JH, Kulik LM, Pruett TL, Seeff LB. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl 2007; 13: 122-129 [PMID: 17192908 DOI: 10.1002/lt.20995]
171. Schmeding M, Neumann UP, Puhl G, Bahra M, Neuhaus R, Neuhaus P. Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: a single-center study of 289 patients. Liver Transpl 2007; 13: 687-692 [PMID: 17457911 DOI: 10.1002/lt.21138]
172. Selzner N, Girgrah N, Lilly L, Guindi M, Selzner M, Therapondos G, Adeyi O, McGilvray I, Cattral M, Greig PD, Grant D, Levy G, Renner EL. The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age. Liver Transpl 2008; 14: 1778-1786 [PMID: 19025914 DOI: 10.1002/lt.21598]
173. Jain A, Singhal A, Kashyap R, Safadjou S, Ryan CK, Orloff MS. Comparative analysis of hepatitis C recurrence and fibrosis progression between deceased-donor and living-donor liver transplantation: 8-year longitudinal follow-up. Transplantation 2011; 92: 453-460 [PMID: 21799468 DOI: 10.1097/TP.0b013e3182259282]
174. Akamatsu N, Sugawara Y. Liver transplantation and hepatitis C. Int J Hepatol 2012; 2012: 686135 [PMID: 22900194 DOI: 10.1155/2012/686135]
175. Berenguer M, Prieto M, San Juan F, Rayón JM, Martinez F, Carrasco D, Moya A, Orbis F, Mir J, Berenguer J. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202-210 [PMID: 12085366 DOI: 10.1053/jhep.2002.33993]
176. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002; 51: 248-252 [PMID: 12117889 DOI: 10.1136/gut.51.2.248]
177. Khapra AP, Agarwal K, Fiel MI, Kontorinis N, Hossain S, Emre S, Schiano TD. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts. Liver Transpl 2006; 12: 1496-1503 [PMID: 16964597 DOI: 10.1002/lt.20849]
178. Rayhill SC, Wu YM, Katz DA, Voigt MD, Labrecque DR, Kirby PA, Mitros FA, Kalil RS, Miller RA, Stolpen AH, Schmidt WN. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C. Transplantation 2007; 84: 331-339 [PMID: 17700157 DOI: 10.1097/01.tp.0000270313.31328.63]
179. Maluf DG, Edwards EB, Stravitz RT, Kauffman HM. Impact of the donor risk index on the outcome of hepatitis C virus-positive liver transplant recipients. Liver Transpl 2009; 15: 592-599 [PMID: 19479802 DOI: 10.1002/lt.21699]
180. Lake JR, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Wiesner RH. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant 2005; 5: 549-557 [PMID: 15707410 DOI: 10.1111/j.1600-6143.2005.00741]
181. Belli LS, Burroughs AK, Burra P, Alberti AB, Samonakis D, Cammà C, De Carlis L, Minola E, Quaglia A, Zavaglia C, Vangeli M, Patch D, Dhillon A, Cillo U, Guido M, Fagiuoli S, Giacomoni A, Slim OA, Airoldi A, Boninsegna S, Davidson BR, Rolles K, Pinzello G. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl 2007; 13: 733-740 [PMID: 17370330 DOI: 10.1002/lt.21093]
182. Avolio AW, Cillo U, Salizzoni M, De Carlis L, Colledan M, Gerunda GE, Mazzaferro V, Tisone G, Romagnoli R, Caccamo L, Rossi M, Vitale A, Cucchetti A, Lupo L, Gruttadauria S, Nicolotti N, Burra P, Gasbarrini A, Agnes S. Balancing donor and recipient risk factors in liver transplantation: the value of D-MELD with particular reference to HCV recipients. Am J Transplant 2011; 11: 2724-2736 [PMID: 21920017 DOI: 10.1111/j.1600-6143.2011.03732]
183. Arenas JI, Vargas HE, Rakela J. The use of hepatitis C-infected grafts in liver transplantation. Liver Transpl 2003; 9: S48-S51 [PMID: 14586895 DOI: 10.1053/jlts.2003.50252]
184. Berenguer M. Risk of extended criteria donors in hepatitis C virus-positive recipients. Liver Transpl 2008; 14 Suppl 2: S45-S50 [PMID: 18825715 DOI: 10.1002/lt.21617]
185. Northup PG, Argo CK, Nguyen DT, McBride MA, Kumer SC, Schmitt TM, Pruett TL. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. Transpl Int 2010; 23: 1038-1044 [PMID: 20444239 DOI: 10.1111/j.1432-2277.2010.01092]
186. Ballarin R, Cucchetti A, Spaggiari M, Montalti R, Di Benedetto F, Nadalin S, Troisi RI, Valmasoni M, Longo C, De Ruvo N, Cautero N, Cillo U, Pinna AD, Burra P, Gerunda GE. Long-term follow-up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: a European multicentric case-control study. Transplantation 2011; 91: 1265-1272 [PMID: 21478815 DOI: 10.1097/TP.0b013e318219eb8f]
187. Wilson S, Mangus RS, Tector A, Fridell JA, Vianna R, Liangpunsakul S, Misra V, Bhardwaj S, Kwo P. Use of infected liver donors in liver transplantation: a case-control study. Gastroenterology 2007; 132: A278
188. Briceño J, Ciria R, Pleguezuelo M, de la Mata M, Muntané J, Naranjo A, Sánchez-Hidalgo J, Marchal T, Rufián S, López-Cillero P. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis. Liver Transpl 2009; 15: 37-48 [PMID: 19109846 DOI: 10.1002/lt.21566]
189. Subramanian V, Seetharam AB, Vachharajani N, Tiriveedhi V, Angaswamy N, Ramachandran S, Crippin JS, Shenoy S, Chapman WC, Mohanakumar T, Anderson CD. Donor graft steatosis influences immunity to hepatitis C virus and allograft outcome after liver transplantation. Transplantation 2011; 92: 1259-1268 [PMID: 22011763 DOI: 10.1097/TP.0b013e318235a1ab]
190. Botha JF, Thompson E, Gilroy R, Grant WJ, Mukherjee S, Lyden ER, Fox IJ, Sudan DL, Shaw BW, Langnas AN. Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation. Liver Int 2007; 27: 758-763 [PMID: 17617118 DOI: 10.1111/j.1478-3231.2007.01490]
191. Burra P, Loreno M, Russo FP, Germani G, Galligioni A, Senzolo M, Cillo U, Zanus G, Fagiuoli S, Rugge M. Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. Liver Transpl 2009; 15: 619-628 [PMID: 19479805 DOI: 10.1002/lt.21761]
192. Baron PW, Sindram D, Higdon D, Howell DN, Gottfried MR, Tuttle-Newhall JE, Clavien PA. Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation. Liver Transpl 2000; 6: 407-412 [PMID: 10915160 DOI: 10.1053/jlts.2000.7581]
193. Watt KD, Lyden ER, Gulizia JM, McCashland TM. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome. Liver Transpl 2006; 12: 134-139 [PMID: 16382465 DOI: 10.1002/lt.20583]
194. Briceño J, Ciria R, Pleguezuelo M, Naranjo A, Sánchez-Hidalgo J, Ruiz-Rabelo J, López-Cillero P, Luque A, de la Mata M, Rufián S. Contribution of marginal donors to liver transplantation for hepatitis C virus infection. Transplant Proc 2007; 39: 2297-2299 [PMID: 17889169 DOI: 10.1016/j.transproceed.2007.07.069]
195. Killackey MT, Gondolesi GE, Liu LU, Paramesh AS, Thung SN, Suriawinata A, Nguyen E, Roayaie S, Schwartz ME, Emre S, Schiano TD. Effect of ischemia-reperfusion on the incidence of acute cellular rejection and timing of histologic hepatitis C virus recurrence after liver transplantation. Transplant Proc 2008; 40: 1504-1510 [PMID: 18589139 DOI: 10.1016/j.transproceed.2008.03.101]
196. Gomez D, Homer-Vanniasinkam S, Graham AM, Prasad KR. Role of ischaemic preconditioning in liver regeneration following major liver resection and transplantation. World J Gastroenterol 2007; 13: 657-670 [PMID: 17278187]
197. Desai KK, Dikdan GS, Shareef A, Koneru B. Ischemic preconditioning of the liver: a few perspectives from the bench to bedside translation. Liver Transpl 2008; 14: 1569-1577 [PMID: 18975290 DOI: 10.1002/lt.21630]
198. Gurusamy KS, Kumar Y, Sharma D, Davidson BR. Ischaemic preconditioning for liver transplantation. Cochrane Database Syst Rev 2008; (1): CD006315 [PMID: 18254099 DOI: 10.1002/14651858.CD006315.pub2]
199. Gurusamy KS, Tsochatzis E, Toon CD, Xirouchakis E, Burroughs AK, Davidson BR. Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus. Cochrane Database Syst Rev 2013; 12: CD006803 [PMID: 24307460 DOI: 10.1002/14651858.CD006803.pub4]
200. Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, Yataco ML, Satyanarayana R, Rosser BG, Vargas HE, Charlton MR, Keaveny AP. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl 2013; 19: 690-700 [PMID: 23696372 DOI: 10.1002/lt.23669]
201. Fontana RJ, Hughes EA, Bifano M, Appelman H, Dimitrova D, Hindes R, Symonds WT. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013; 13: 1601-1605 [PMID: 23593993 DOI: 10.1111/ajt.12209]